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Abstract  
This study was a retrospective multicentre cohort study of patients with COVID-19 
diagnosed at 24 hospitals in Jiangsu province, China as of 15 March 2020. The primary 
outcome was the occurrence of acute respiratory failure during hospital stay. Of 625 patients, 
56 (9%) had respiratory failure. Some selected demographic, epidemiologic, clinical and 
laboratory features as well as radiologic features at admission and treatment during 
hospitalisation were significantly different in patients with and without respiratory failure. 
The multivariate logistic analysis indicated that age (in years) (Odds ratio [OR], 1.07; 95% 
confidence interval [CI]: 1.03–1.10; P = 0.0002), respiratory rate (breaths/minute) (OR, 1.23; 
95% CI: 1.08–1.40; P = 0.0020), lymphocyte count (10
9
/L) (OR, 0.18; 95% CI: 0.05–
0.69; P = 0.0157), and pulmonary opacity score (per 5%) (OR, 1.38; 95% CI: 1.19–1.61; P < 
0.0001) at admission were associated with the occurrence of respiratory failure. Older age, 
increased respiratory rate, decreased lymphocyte count and greater pulmonary opacity score 
at admission were independent risk factors of respiratory failure in patients with COVID-19. 
Patients having these risk factors need to be intensively managed during hospitalisation. 













The major clinical effects of COVID-19 infection are on the respiratory system although 
other systems can be affected [1, 2]. COVID-19 may result in acute respiratory failure 
requiring mechanical ventilation and even leading to death [3-6]. A study in Italy reported 
rates of respiratory failure as high as 29%-40% [7]. The 28-day mortality could occur in 
26%-30% of patients with COVID-19 who had respiratory failure necessitating invasive 
mechanical ventilation (IMV) [8]. Since the COVID-19 pandemic is still evolving, the true 
mortality has not been defined, but the crude mortality ratio (the number of reported deaths 
divided by the number of reported cases) has been estimated to be 3%-4%, which appears to 
be higher than that for influenza [9]. However, the infection mortality rate (the number of 
reported deaths divided by the number of infections) is lower than the crude mortality ratio; 
and the mortality rate varies among different regions, demographic and socioeconomic 
characteristics, levels of healthcare access and quality, intervention methods, and qualities of 
reported deaths and cases [9-11]. Identifying risk factors of respiratory failure in patients with 
COVID-19 could help clinicians recognise patients at high risk of respiratory failure and 
hence take active treatment for them to prevent further worse outcomes and reduce 
emergency intubation or cardiopulmonary resuscitation to protect medical staff from related 
infections.  
For patients with COVID-19, risk factors of severe COVID-19, admission to intensive care 
unit (ICU) and death have been reported in many studies [12-15], but studies on risk factors 
of respiratory failure remain scarce. To the best of our knowledge, only two studies are 
available in the literature identifying the predictors of respiratory failure and both studies 
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were conducted in Italy [7, 16]. However, demographic characteristics may vary across 
different countries, and the levels and risk factors of respiratory failure may also differ [17]. 
Therefore, information on the respiratory failure in other settings than Italy will be of great 
academic and clinical value. 
Based on a large multicentre retrospective cohort with rich information on demographic, 
epidemiologic, clinical and laboratory features as well as CT imaging features, this study 




Study Design and Participants 
The study design and participants have been described in our previous study [18]. Here we 
briefly describe it. This is a retrospective multicentre cohort study. Patient inclusion criterion 
was as of 15
th
 March 2020, all patients diagnosed with COVID-19 at 24 hospitals designated 
to treat COVID-19 in Jiangsu province, China according to the diagnostic criteria of the 
“Diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 7)” 
released by National Health Commission and National Administration of Traditional Chinese 
Medicine of China [19]. The diagnosis of COVID-19 was based on epidemiological history, 
clinical and CT manifestations, and laboratory confirmation (real–time reverse transcriptase–
polymerase chain reaction assays [RT-PCR] to detect etiological agent severe acute 
respiratory syndrome coronavirus-2, SARS-CoV-2, which caused COVID-19) [11, 19]. The 
exclusion criterion was patients with no available medical records. The criteria for discharge 
were: the patient's body temperature remained normal for more than 3 days, the symptoms 
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were relieved (if there were symptoms), and the results of two consecutive RT-PCR assays 
were negative (throat swab samples, at least 1 day apart). 
 
Data collection and definition of variables 
The primary outcome was the occurrence of acute respiratory failure during 14-day follow-up 
(days 1, 2, 3, 4, 5, 6, 7 and 14 from admission). The respiratory failure was defined as oxygen 
saturation (SpO2) <93% and/or partial pressure of oxygen in arterial blood (PaO2) <60 mmHg 
on room air and/or requirement of high-flow nasal cannula oxygen therapy (HFNC), non-
invasive or invasive mechanical ventilation. Type 1 (hypoxemic) respiratory failure refers to 
the hypoxemia (PaO2 <60 mmHg [8 kPa]) with the normal (normocapnia) or low 
(hypocapnia) partial pressure of carbon dioxide (PaCO2) in arterial blood. Type 2 
(hypercapnic) respiratory failure refers to the hypoxemia with the hypercapnia (PaCO2 >45 
mm Hg [6 kPa]).  
Demographic features analysed in this study included sex and age (year). Epidemiologic 
features included exposure types (imported case or local case) and types of disease onset 
(single onset or clustered onset). Clinical features included initial symptoms (fever, cough, 
sputum, shortness of breath, anorexia, and diarrhoea), medical history (hypertension, 
coronary heart disease, diabetes, stroke, smoking, and drinking), and vital signs (temperature 
[°C], heart rate [HR, beats/minute], systolic blood pressure [SBP, mmHg], diastolic blood 
pressure [DBP, mmHg], respiratory rate [breaths/minute], and SpO2 [%]). Laboratory 





/L], lymphocyte count [10
9
/L], haemoglobin [g/L], and platelet count [10
9
/L]), 
organ function parameters (albumin [g/L] and creatinine [umol/L]), inflammatory factors (C-
reactive protein [mg/L]), and coagulation function parameters (activated partial 
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thromboplastin time [APTT, s], fibrinogen [g/L], and D-dimer [mg/L]). Radiologic features 
included lesion distribution (outer third of lung involved, middle third of lung involved, or 
inner third of lung involved), lesion density (below 20% consolidation, 20% to 80% 
consolidation, or above 80% consolidation), lesion border (well-defined border, moderately 
defined border, or ill-defined border), quadrant score, and pulmonary opacity score. Data of 
features listed above were collected at admission. Data of treatments (supportive treatments 
and medication) were obtained within the whole study period.  
Imported cases were defined as those who had been to the pandemic centre of China (Wuhan 
city), or had contact with people or patients with COVID-19 who had been to Wuhan; and 
other cases were classified as “local cases”. A clustered onset is defined as the occurrence of 
two or more confirmed COVID-19 cases in the same cluster/group within 14 days, such as 
family, community, hospital, workplace or public place. A clustered onset may occur from 
interpersonal transmission via close contact with or joint contact with a confirmed COVID-19 
case. Other cases not meeting the criteria for a clustered onset were classified as “single 
onset”. 
Radiologic features were evaluated visually, by two radiologists with more than 5 years’ 
working experience. The radiologists were blinded to patients’ other characteristics and 
would reach agreements on different assessments of radiologic features. Chest CT axial 
sections were divided into four quadrants (left, right, anterior and posterior) by drawing 
horizontal and vertical lines through the centre of the chest. The quadrant score was defined 
as the number of quadrants with pulmonary opacities extending from the proximal end to the 
distal end of the chest, ranging from 0 to 4; and pulmonary opacity score was defined as the 
percentage of pulmonary opacity area in the area of bilateral lungs, rounded to the nearest 5%. 
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Normally distributed continuous variables and skewed distributed continuous variables of 
patients were reported as mean (standard deviation, SD) and median (interquartile range, IQR) 
by group (patients with and without respiratory failure) and compared using Student's t-test or 
Mann-Whitney U test, respectively. Categorical variables were summarised using frequency 
and percentage and compared by χ
2 
or Fisher exact test.  
Logistic regression models were used to identify risk factors of having respiratory failure. 
Univariate logistic regression models were fitted first to evaluate associations between each 
variable measured at admission and respiratory failure on the complete cases (without 
missing value). Variables that were statistically significant in the univariate analysis were 
then included in the multivariate logistic regression model. In the multivariate analysis, 
missing covariates were imputed with multiple imputation using a Markov Chain Monte 
Carlo simulation method with 10 iterations. A sensitivity analysis was performed on 
complete cases. Odds ratio (OR) of having respiratory failure for each variable was calculated 
along with 95% confidence interval (CI). The 2-tailed P < 0.05 was considered as statistically 
significant. The analyses were performed using SAS 9.4 (SAS Institute). 
 
Results 
Of the 721 suspected cases with possible COVID-19 in Jiangsu province from 10
th
 January to 
15
th
 March 2020, 90 cases were excluded since RT-PCR tests showed negative results and 6 
cases were excluded due to no available medical records. Finally 625 cases (52.6% male; 
median age 46 years old [IQR 32-57]) in 24 hospitals were included for analysis, mainly from 
the Second Hospital of Nanjing, Suzhou Infectious Disease Hospital and Huai'an No.4 
People's Hospital (113 [18.1%], 86 [13.8%] and 79 [12.6%], respectively). The remaining 
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cases were disproportionately from the other hospitals. The hospital to which a patient was 
admitted was mainly determined by geographic location. Of the 625 patients, 56 (9%) had 
respiratory failure, mainly type I (hypoxemic). At the study end point (15
th
 March 2020), no 
patients died and all patients were discharged from hospitals.  
At admission to hospital, compared with patients without respiratory failure, those with 
respiratory failure were significantly older (mean age 59.70 vs. 42.93 years, P < 0.0001); 
were more likely to be single onset (62.5% vs. 48.3%, P = 0.0498); were more likely to have 
symptoms including fever (82.1% vs. 64.3%, P = 0.0074), cough (71.4% vs. 53.4%, P = 
0.0110), sputum (42.9% vs 25.0%, P = 0.0064), and shortness of breath (12.5% vs. 2.3%, P = 
0.0010); were more likely to have prior histories of hypertension (32.1% vs. 13.9%, P = 
0.0014), coronary heart disease (7.1% vs. 1.6%, P = 0.0224), and diabetes (17.9% vs. 5.3%, 
P = 0.0015); had higher mean temperature (37.25 vs. 37.03 °C, P = 0.0347), greater mean 
heart rate (90.71 vs. 86.82 beats/minute, P = 0.0387), greater mean respiratory rate (21.13 vs. 
18.88 breaths/minute, P < 0.0001), and lower mean SpO2 (95.27% vs. 97.92%, P < 0.0001) 
(Table 1). 









/L, P = 0.0008), 
and median albumin levels (40.0 vs. 41.9 g/L, P = 0.0005). In addition, patients with 
respiratory failure had significantly higher median levels of C-reactive protein (40.6 vs. 10.0 
mg/L, P < 0.0001), median fibrinogen levels (4.3 vs. 3.4 g/L, P < 0.0001), and median D-
dimer levels (0.3 vs. 0.2 mg/L, P = 0.0004) (Table 2). 
For visually evaluated CT features at hospital admission, patients with respiratory failure had 
significantly greater median of CT quadrant score (4.00 vs. 2.00, P < 0.0001) and median of 
pulmonary opacity score (52.50% vs. 20.00%, P < 0.0001) (Table 3). 
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Oxygen was delivered to patients with respiratory failure via nasal cannula (80.4%), simple 
face masks (23.2%), HFNC (39.3%), non-invasive mechanical ventilation (NIV) (53.6%), 
IMV (8.9%), and in prone position (30.4%) (Table 4). Patients with respiratory failure were 
more likely to receive supportive treatments and medications (all P < 0.05), except for the 
interferon. 
Twenty variables at admission were found to be related to the occurrence of respiratory 
failure in univariate logistic regression analysis (Table 5). When they were included in the 
multivariate logistic regression model simultaneously, four variables were independently 
related to the occurrence of respiratory failure: age (in years) (OR, 1.07; 95% CI: 1.03–
1.10; P = 0.0002), respiratory rate (breaths/minute) (OR, 1.23; 95% CI: 1.08–1.40; P = 
0.0020), lymphocyte count (10
9
/L) (OR, 0.18; 95% CI: 0.05–0.69; P = 0.0157), and 
pulmonary opacity score (per 5%) (OR, 1.38; 95% CI: 1.19–1.61; P < 0.0001). 
The sensitivity logistic regression model with only above four significant variables was 




This study assessed the level and risk factors of respiratory failure among patients with 
COVID-19. During the 14-day follow-up, 9% (56 out of 625) of patients with COVID-19 
suffered from respiratory failure (mainly type I, hypoxemic) in Jiangsu province, China. At 
the end of the study (15
th
 March 2020), no patients died and all patients were discharged from 
hospitals. Among many factors explored in this study, four of them (older age, increased 
respiratory rate, decreased lymphocyte count and greater pulmonary opacity score) were 
identified as independent risk factors of respiratory failure after controlling for other 
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confounders. Therefore, patients with such factors need to be carefully and thoroughly 
managed by physicians.  
Jiangsu province is non-neighbouring with and geographically distant around 600 km from 
Hubei province, where Wuhan city (the epicentre of COVID-19 pandemic in China) located 
in. The rate of respiratory failure in Jiangsu province is similar to the figure in the national 
report from China [20] but this rate is much lower than reported earlier in Wuhan city (26%–
32%) [5, 21]. This may be due to the early responses and measures adopted by the Jiangsu 
provincial health authorities to deal with the disease during the pandemic, including more 
adequate medical resources, deeper understanding and better management of respiratory 
failure for patients with COVID-19 [11]. The rate of respiratory failure in this study is also 
lower than reported in other countries, including Italy (29%–40%) [7] and the United States 
(~14%) [17], which may result from variable population demographics [17], and the early 
identification and early treatment of patients at high risk of respiratory failure in Jiangsu 
province [11]. 
Our study found that age was associated with respiratory failure. This is consistent with 
previous studies reporting that middle-aged and elderly patients with COVID-19 were 
susceptible to respiratory failure [4, 7], and is also similar to the results for patients with 
severe acute respiratory syndrome (SARS) [22-24]. A previous study showed that the older 
population have a higher incidence of comorbidities and hence possible poorer immune 
response to COVID-19 and poorer clinical outcomes [25]. This study also found that patients 
with respiratory failure tended to have more comorbidities including hypertension, coronary 
heart disease and diabetes.  
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Increased respiratory rate as a risk factor of respiratory failure identified in this study is 
simple and convenient to apply for clinicians in their practice. This result is consistent with 
previous studies [7, 26].  
In our study, reduced lymphocyte count at admission was strongly associated with respiratory 
failure. Previous studies also show that the lymphocyte count of COVID-19 patients admitted 
to the ICU continued to decline [27, 28], and the reduced lymphocyte count was a risk factor 
for respiratory failure [7]. Reduced lymphocytes may be part of the pathogenesis of COVID-
19 [29, 30]. Therefore, more attention needs to be paid to patients whose lymphocyte count 
decline more severely. Laboratory abnormalities including lymphopenia have been 
previously reported in severe cases of other respiratory viral diseases, including SARS, 
Middle East respiratory syndrome (MERS), and influenza [22, 31-34]. 
All radiologic images collected in our study were CT which have the advantage of high-
resolution transversal imaging and accurate display of the extent and range of lung lesions. 
The potential measurement bias and misclassification bias resulted from visual assessment of 
CT images were controlled by double assessments of CT images by two independent 
radiologists with more than 5 years’ experience in pulmonary imaging, and by discussion and 
reaching agreements on different assessment results. This study showed that the pulmonary 
opacity score, one of the radiologic features, was strongly and independently associated with 
respiratory failure in patients with COVID-19, indicating that the more severe abnormality of 
lung function is an important factor to identify patients at high risks of respiratory failure. 
Former studies demonstrate that CT lung lesions can predict death and ICU admission in 
patients with COVID-19 [13, 35]. On the other hand, this study shows that between patients 
with and without respiratory failure, there were no significant differences in the distribution 
of lung lesions (both were more likely to involve the outer third of lungs), lesion density 
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(both were more likely to have less than 20% of consolidation of lungs), and lesion boundary 
definition (both were more likely to have the ill-defined border of lungs). 
In Jiangsu province with adequate medical material and human resources, all COVID-19 
patients with respiratory failure received ICU monitoring. In comparison, due to limited 
resources at disease outbreak in Spain, some comorbid patients with respiratory failure 
requiring mechanical ventilation and ICU treatment did not receive these treatments which 
were reserved for non-comorbid patients, hence a large number of patients with respiratory 
failure finally died [36]. For similar settings with limited resources, the experience in Jiangsu 
province may be beneficial to COVID-19 patients with respiratory failure: in Jiangsu, a large 
proportion of patients with respiratory failure conducted prone position (30%) and received 
HFNC (40%) or NIV (~50%), which help reduce the further use of IMV (~10%) and 
mortality (no death occurred and all patients were discharged at the end of the study). This 
confirms the findings from several previous small studies [37, 38]. 
This study addressed several limitations of previous studies by (1) adding radiologic features 
and several epidemiologic, clinical, and laboratory features into analysis to reduce residual 
confounding; (2) using multiple imputation method to provide unbiased estimates of levels 
and risk factors; and (3) conducting a sensitivity analysis to confirm that results from 
multivariate logistic regression analysis, from which our main conclusion was drawn, were 
insensitivity to missing data, and hence were robust and credible. This study included 625 
patients from 24 hospitals, i.e. nearly all patients in Jiangsu province, China (a province with 
a population of 80 million; only 6 cases were excluded due to missing medical records), to 
make the findings from this study be subject to less selection bias and be more generalisable 
to populations in similar settings.  
Our study has several limitations. Firstly, this is a retrospective observational study and its 
results may be subject to measurement bias and information bias, and some unobserved 
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confounders (e.g. obesity, gene cluster) [16, 39]. Secondly, some data on laboratory test were 
missing and hence fewer laboratory parameters were included in the analysis. Thirdly, we 
were unable to analyse the impact of medical management on respiratory failure including 
supportive treatments and medication, because of the chronological order and treatment 
information collected before, when, or after respiratory failure occurred. 
 
Conclusions 
In conclusion, this large cohort study based on a representative sample of 625 patients with 
COVID-19 shows that the rate of respiratory failure in Jiangsu province, China (9%), was 
similar to the national level in China, but much lower than in Wuhan city (the epicentre of 
COVID-19 pandemic in China) and some other countries. The study has also identified four 
independent risk factors of respiratory failure in patients with COVID-19 including older age, 
increased respiratory rate, decreased lymphocyte count and greater pulmonary opacity score 
at admission. For successful control of mortality related to COVID-19, patients with COVID-
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Table 1: Epidemiological and clinical characteristics of patients at admission 








Demographic Male, n(%) 329(52.6%) 36(64.3%) 293(51.5%) 0.0700 
 Age (year), mean(SD) 44.44(17.21) 59.70(13.55) 42.93(16.80) <.0001 
Exposure type, n(%) Imported case 219(35.0%) 23(41.1%) 196(34.4%) 0.3784 
 Local case 406(65.0%) 33(58.9%) 373(65.6%)   
Types of disease onset, n(%) Single onset 310(49.6%) 35(62.5%) 275(48.3%) 0.0498 
 Clustered onset 315(50.4%) 21(37.5%) 294(51.7%)   
Initial symptoms, n(%) Fever 412(65.9%) 46(82.1%) 366(64.3%) 0.0074 
 Cough 344(55.0%) 40(71.4%) 304(53.4%) 0.0110 
 Sputum 166(26.6%) 24(42.9%) 142(25.0%) 0.0064 
 Shortness of breath 20(3.2%) 7(12.5%) 13(2.3%) 0.0010 
 Anorexia 13(2.1%) 1(1.8%) 12(2.1%) 1.0000 
 Diarrhoea 53(8.5%) 6(10.9%) 47(8.3%) 0.4516 
Medical history, n(%) Hypertension 97(15.5%) 18(32.1%) 79(13.9%) 0.0014 
 Coronary heart disease 13(2.1%) 4(7.1%) 9(1.6%) 0.0224 
 Diabetes 40(6.4%) 10(17.9%) 30(5.3%) 0.0015 
 Stroke 9(1.4%) 2(3.6%) 7(1.2%) 0.1900 
 Smoke 25(4.0%) 0(0.0%) 25(4.4%) 0.1547 
 Drinking 30(4.8%) 1(1.8%) 29(5.1%) 0.5066 
Vital signs, mean(SD) Temperature (°C) 37.05(0.73) 37.25(0.90) 37.03(0.71) 0.0347 
 HR (beats/minute) 87.17(13.46) 90.71(15.24) 86.82(13.24) 0.0387 
 SBP (mmHg) 128.83(15.66) 131.16(18.89) 128.60(15.31) 0.2430 
 DBP (mmHg) 81.47(10.51) 78.95(9.67) 81.72(10.57) 0.0596 
 Respiratory rate (breaths/minute) 19.08(2.56) 21.13(5.03) 18.88(2.07) <.0001 
 SpO2 (%) 97.68(1.99) 95.27(4.95) 97.92(1.16) <.0001 
 
SD, standard deviation; HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood; SpO2, peripheral capillary oxygen saturation.  
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0950268821000157






Table 2: Laboratory parameters at hospital admission 
 
 N,median(IQR)  
 Respiratory failure  
Category Parameters All Yes No P-value 
Blood test WBC count (10
9
/L) 513,4.9(3.9-6.2) 45,4.5(3.4-5.8) 468,4.9(3.9-6.3) 0.1742 
 Neutrophil (10
9
/L) 507,3.0(2.2-4.0) 45,3.1(2.1-4.6) 462,3.0(2.2-4.0) 0.3912 
 Lymphocyte (10
9
/L) 505,1.3(0.9-1.7) 45,0.7(0.5-0.9) 460,1.3(1.0-1.8) <.0001 
















Organ function Albumin (g/L) 480,41.4(38.0-45.1) 41,40.0(34.0-41.4) 439,41.9(38.0-45.6) 0.0005 
 Creatinine (umol/L) 476,63.9(51.0-79.0) 42,62.4(49.1-85.0) 434,64.0(51.0-78.8) 0.9785 
Inflammatory factors C-reactive protein (mg/L) 474,10.0(2.7-22.6) 39,40.6(7.6-106.6) 435,10.0(2.6-19.7) <.0001 
Coagulation function APTT (s) 513,32.2(28.0-37.2) 47,32.0(28.0-36.6) 466,32.2(28.0-37.3) 0.7284 
 Fibrinogen (g/L) 496,3.5(2.7-4.2) 46,4.3(3.0-6.1) 450,3.4(2.7-4.2) <.0001 
 D-dimer (mg/L) 475,0.2(0.1-0.4) 44,0.3(0.2-1.1) 431,0.2(0.1-0.4) 0.0004 
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Respiratory failure, n(%) or 
median(IQR)  
Category Measurements All Yes No P-value 
Lesion distribution* Outer third of lung involved 400(82.6%) 39(84.8%) 361(82.4%) 0.6873 
 Middle third of lung involved 278(57.4%) 27(58.7%) 251(57.3%) 0.8561 
 Inner third of lung involved 123(25.4%) 17(37.0%) 106(24.2%) 0.0587 
Lesion density* Below 20% consolidation 205(42.4%) 21(45.7%) 184(42.0%) 0.6343 
 20% to 80% consolidation 89(18.4%) 10(21.7%) 79(18.0%) 0.5375 
 Above 80% consolidation 116(24.0%) 9(19.6%) 107(24.4%) 0.4622 
Lesion border* Well-defined border 90(18.6%) 9(19.6%) 81(18.5%) 0.8589 
 Moderately defined border 82(16.9%) 8(17.4%) 74(16.9%) 0.9320 
 Ill-defined border 235(48.6%) 23(50.0%) 212(48.4%) 0.8365 
Other findings** Quadrant score (0-4) 2.00(1.00-4.00) 4.00(4.00-4.00) 2.00(1.00-4.00) <.0001 
 Pulmonary opacity (%) 20.00(5.00-40.00) 52.50(35.00-75.00) 20.00(5.00-35.00) <.0001 
      
 
 * The total number of cases is 484 (43 respiratory failures and 441 no respiratory failures) 
** The total number of cases is 496 (47 respiratory failures and 449 no respiratory failures). 
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Table 4: Clinical management during hospitalisation 
 
 Respiratory failure  







Supportive treatments, n(%) Inotropic and vasoconstrictive agents 5(0.8%) 5(8.9%) 0(0.0%) <.0001 
 Nasal cannula 221(35.4%) 45(80.4%) 176(30.9%) <.0001 
 Mask 14(2.2%) 13(23.2%) 1(0.2%) <.0001 
 High-flow nasal cannula oxygen therapy 25(4.0%) 22(39.3%) 3(0.5%) <.0001 
 Non-invasive ventilation 34(5.4%) 30(53.6%) 4(0.7%) <.0001 
 Invasive mechanical ventilation 5(0.8%) 5(8.9%) 0(0.0%) <.0001 
 Prone position 18(2.9%) 17(30.4%) 1(0.2%) <.0001 
Medical drugs, n(%) Traditional Chinese medicine 98(15.7%) 29(51.8%) 69(12.1%) <.0001 
 Immunoglobulin 156(25.0%) 41(73.2%) 115(20.2%) <.0001 
 Interferon 503(80.5%) 40(71.4%) 463(81.4%) 0.0787 
 Antioxidants 152(24.3%) 30(53.6%) 122(21.4%) <.0001 
 Glucocorticoid 142(22.7%) 48(85.7%) 94(16.5%) <.0001 
 Thymosin 144(23.0%) 35(62.5%) 109(19.2%) <.0001 
 Neurotrophic drugs 102(16.3%) 19(33.9%) 83(14.6%) 0.0009 
 Any antibiotics 336(53.8%) 53(94.6%) 283(49.7%) <.0001 
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Table 5: Factors associated with respiratory failure in patients with COVID-19: Results from logistic regression analysis 
 
 Univariate analysis* Multivariate analysis** 
Variables OR (95%CI) P-value OR (95%CI) P-value 
Age (year) 1.07(1.05,1.09) <.0001 1.07(1.03,1.10) 0.0002 
Clustered onset 0.56(0.32,0.99) 0.0453 1.11(0.45,2.71) 0.8202 
Fever 2.55(1.26,5.16) 0.0092 1.69(0.60,4.71) 0.3176 
Cough 2.18(1.19,3.98) 0.0113 1.20(0.46,3.16) 0.7081 
Sputum 2.26(1.29,3.96) 0.0046 1.45(0.55,3.86) 0.4520 
Shortness of breath 6.11(2.33,16.02) 0.0002 0.82(0.15,4.59) 0.8242 
Hypertension 2.94(1.60,5.40) 0.0005 0.80(0.30,2.13) 0.6589 
Diabetes 3.91(1.80,8.49) 0.0006 2.13(0.59,7.68) 0.2469 
Coronary heart disease 4.79(1.43,16.08) 0.0113 4.60(0.78,27.20) 0.0925 
Temperature (°C) 1.44(1.02,2.03) 0.0362 0.67(0.39,1.17) 0.1607 
HR (beats/minute) 1.02(1.00,1.04) 0.0394 1.00(0.96,1.03) 0.7733 
Respiratory rate (breaths/minute) 1.25(1.15,1.37) <.0001 1.23(1.08,1.40) 0.0020 
Lymphocyte (10
9
/L) 0.02(0.01,0.07) <.0001 0.18(0.05,0.69) 0.0157 
Platelet (10
9
/L) 0.99(0.98,1.00) 0.0026 1.00(0.99,1.01) 0.9590 
Albumin (g/L) 0.92(0.87,0.96) 0.0007 1.02(0.93,1.11) 0.7318 
C-reactive protein (mg/L) 1.02(1.01,1.03) <.0001 1.00(0.99,1.01) 0.6707 
Fibrinogen (g/L) 1.88(1.50,2.37) <.0001 0.95(0.64,1.41) 0.8005 
D-dimer (mg/L) 1.33(1.10,1.60) 0.0035 1.15(0.78,1.71) 0.4824 
Quadrant score (0-4) 2.37(1.71,3.28) <.0001 0.80(0.46,1.40) 0.4331 
Pulmonary opacity (per 5%) 1.40(1.29,1.52) <.0001 1.38(1.19,1.61) <.0001 
 
* Univariate analysis is based on the complete cases without missing value. 
** Multivariate analysis is based on imputed values for missing data in lymphocyte, platelet, albumin, C-reactive protein, fibrinogen, D-
dimer, quadrant score and pulmonary opacity using multiple imputation method. 
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